98 related articles for article (PubMed ID: 23350850)
21. Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection.
Cimini E; Bonnafous C; Bordoni V; Lalle E; Sicard H; Sacchi A; Berno G; Gioia C; D'Offizi G; Visco Comandini U; Vlassi C; Capobianchi MR; Martini F; Agrati C
PLoS One; 2012; 7(5):e37014. PubMed ID: 22629350
[TBL] [Abstract][Full Text] [Related]
22. Activation of Type I and Type III Interferons in Chronic Hepatitis C.
Mihm S
J Innate Immun; 2015; 7(3):251-259. PubMed ID: 25766746
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
24. [Characteristics of immune response to etiotropic and pathogenetic therapy in children with chronic hepatitis C].
Vasil'eva DK; Goriacheva LG; Monakhova NE
Eksp Klin Farmakol; 2011; 74(12):33-5. PubMed ID: 22379880
[TBL] [Abstract][Full Text] [Related]
25. Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.
Berry CM
Cytokine Growth Factor Rev; 2016 Oct; 31():83-90. PubMed ID: 27544015
[TBL] [Abstract][Full Text] [Related]
26. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency.
Foster GR; Rodrigues O; Ghouze F; Schulte-Frohlinde E; Testa D; Liao MJ; Stark GR; Leadbeater L; Thomas HC
J Interferon Cytokine Res; 1996 Dec; 16(12):1027-33. PubMed ID: 8974005
[TBL] [Abstract][Full Text] [Related]
27. Development and biological activity of long-acting recombinant human interferon-α2b.
Zhang Q; Wang C; Ma F; Yao L; Gao H; Zhu L; Zheng L
BMC Biotechnol; 2020 Mar; 20(1):16. PubMed ID: 32169063
[TBL] [Abstract][Full Text] [Related]
28. Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder.
El-Baky NA; Uversky VN; Redwan EM
Cytokine Growth Factor Rev; 2015 Dec; 26(6):637-45. PubMed ID: 26169931
[TBL] [Abstract][Full Text] [Related]
29. Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases.
Giorgetti SI; Etcheverrigaray M; Terry F; Martin W; De Groot AS; Ceaglio N; Oggero M; Mufarrege EF
Clin Immunol; 2021 Dec; 233():108888. PubMed ID: 34798238
[TBL] [Abstract][Full Text] [Related]
30. In vitro sensitivity of human metapneumovirus to type I interferons.
Scagnolari C; Trombetti S; Selvaggi C; Carbone T; Monteleone K; Spano L; Di Marco P; Pierangeli A; Maggi F; Riva E; Antonelli G
Viral Immunol; 2011 Apr; 24(2):159-64. PubMed ID: 21449726
[TBL] [Abstract][Full Text] [Related]
31. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies.
Hanley JP; Haydon GH
Leuk Lymphoma; 1998 Apr; 29(3-4):257-68. PubMed ID: 9684924
[TBL] [Abstract][Full Text] [Related]
32. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection.
Li SF; Gong MJ; Zhao FR; Shao JJ; Xie YL; Zhang YG; Chang HY
Cell Physiol Biochem; 2018; 51(5):2377-2396. PubMed ID: 30537741
[TBL] [Abstract][Full Text] [Related]
33. Antiviral activity of transiently expressed IFN-kappa is cell-associated.
Buontempo PJ; Jubin RG; Buontempo CA; Wagner NE; Reyes GR; Baroudy BM
J Interferon Cytokine Res; 2006 Jan; 26(1):40-52. PubMed ID: 16426147
[TBL] [Abstract][Full Text] [Related]
34. Molecular and biologic characterization of recombinant interferon-alpha2b.
Bordens R; Grossberg SE; Trotta PP; Nagabhushan TL
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-41-S9-51. PubMed ID: 9208872
[TBL] [Abstract][Full Text] [Related]
35. The biological properties, assay, and standardization of interferon-alpha: a need for a WHO collaborative study.
Mire-Sluis AR; Gaines Das R; Zoon K; Padilla A; Thorpe R; Meager A
J Interferon Cytokine Res; 1996 Aug; 16(8):637-43. PubMed ID: 8877735
[TBL] [Abstract][Full Text] [Related]
36. Development of a highly purified multicomponent leukocyte IFN-alpha product.
Tölö H; Kauppinen HL; Alm G; Perers A; Lindeberg E; Wahlstedt-Fröberg V; Parkkinen J
J Interferon Cytokine Res; 2001 Nov; 21(11):913-20. PubMed ID: 11747623
[TBL] [Abstract][Full Text] [Related]
37. IFN-α subtypes: distinct biological activities in anti-viral therapy.
Gibbert K; Schlaak JF; Yang D; Dittmer U
Br J Pharmacol; 2013 Mar; 168(5):1048-58. PubMed ID: 23072338
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology and therapeutic potential of interferons.
George PM; Badiger R; Alazawi W; Foster GR; Mitchell JA
Pharmacol Ther; 2012 Jul; 135(1):44-53. PubMed ID: 22484806
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.
Rycroft D; Sosabowski J; Coulstock E; Davies M; Morrey J; Friel S; Kelly F; Hamatake R; Ovečka M; Prince R; Goodall L; Sepp A; Walker A
PLoS One; 2015; 10(2):e0117847. PubMed ID: 25689509
[TBL] [Abstract][Full Text] [Related]
40. Bioconjugation strategies and clinical implications of Interferon-bioconjugates.
Hauptstein N; Meinel L; Lühmann T
Eur J Pharm Biopharm; 2022 Mar; 172():157-167. PubMed ID: 35149191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
